Formycon AG is a leading independent developer of biosimilars, which are highly similar, clinically equivalent versions of approved biopharmaceuticals. The company's pipeline includes biosimilar candidates targeting blockbuster biologic drugs in therapeutic areas such as ophthalmology, immunology, and oncology. Notable programs include biosimilars referencing Lucentis (ranibizumab), Stelara (ustekinumab), Eylea (aflibercept), and Keytruda (pembrolizumab). Formycon covers the entire biosimilar development value chain, from cell line development and analytics to clinical trials and regulatory approval. The company operates primarily out of Germany and generates revenue through licensing agreements, milestone payments, and royalties from global commercialization partners.
